|1.||Staels, Bart: 27 articles (07/2015 - 01/2002)|
|2.||Cuzzocrea, Salvatore: 24 articles (01/2013 - 07/2002)|
|3.||Wahli, Walter: 18 articles (04/2015 - 02/2002)|
|4.||Michalik, Liliane: 14 articles (06/2015 - 01/2003)|
|5.||Esposito, Emanuela: 14 articles (01/2013 - 01/2006)|
|6.||Mazzon, Emanuela: 13 articles (07/2012 - 12/2004)|
|7.||Hontecillas, Raquel: 13 articles (01/2012 - 06/2006)|
|8.||Bassaganya-Riera, Josep: 13 articles (01/2012 - 06/2006)|
|9.||Staels, B: 13 articles (01/2008 - 05/2000)|
|10.||Vázquez-Carrera, Manuel: 12 articles (03/2015 - 02/2005)|
10/01/2010 - "Accordingly, RSG appears to produce pleiotropic protective effects on the peritoneal membrane by reducing the accumulation of AGEs and inflammation, and by preserving the mesothelial cells monolayer, highlighting the potential of PPAR-γ activation to ameliorate peritoneal deterioration in PD patients."
11/01/2015 - "These studies unravel a novel function of PPAR-γ in controlling biliary epithelium inflammation and suggest that impaired activation of PPAR-γ contributes to the chronic inflammatory state of CFTR-defective cholangiocytes. "
03/01/2015 - "Several studies have revealed that PPAR-γ is also involved in the regulation of oxidative stress and chronic inflammation associated with aging process in vivo as well as with cellular senescence in vitro. "
01/01/2013 - "This study aimed to evaluate the attenuation of inflammation by PPAR-α and to investigate the interaction between PPAR-α and TLR pathways in AP. "
11/01/2012 - "Recent studies have shown that peroxisome proliferator-activated receptors (PPARs), in particular PPARs α and γ, regulate fat content of the liver together with the anti-oxidant and anti-inflammation systems. "
01/01/2008 - "Improved Insulin Resistance and Lipid Metabolism by Cinnamon Extract through Activation of Peroxisome Proliferator-Activated Receptors."
09/25/2015 - "Consistent with previous studies, peroxisome proliferator-activated receptor (PPAR) γ agonism reversed TNFα-induced insulin resistance. "
09/01/2015 - "Peroxisome proliferator‑activated receptor (PPAR)δ is an important regulator of energy metabolism and insulin resistance in diabetes. "
01/01/2014 - "Thus, our results indicate that CRE can be used to prevent from the TNF-α-induced insulin resistance through PPAR-γ pathways. "
05/01/2013 - "In liver, PPAR-γ expression correlated with insulin resistance index in offspring from RV (r=-0.62, P<.05), but not in those from HV dams (r=0.13, P>.05). "
12/01/2011 - "Hence, potent PPAR-α agonists might be useful in the treatment of renal fibrosis."
12/01/2011 - "This Commentary discusses new findings by Boor et al., who show that BAY PP1, a novel PPAR-α agonist, ameliorates renal fibrosis and dysfunction."
02/01/2014 - "A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses."
12/01/2011 - "Thus, renal fibrosis is characterized by a reduction of PPAR-α expression, and treatment with BAY PP1 restores PPAR-α expression and ameliorates renal fibrosis by modulating the cross-talk between tubular cells and fibroblasts. "
11/01/2014 - "While there is an unmet therapeutical need for NASH and fibrosis, recent preclinical studies showed that peroxisome proliferator-activated receptor (PPAR)-α agonism can efficiently oppose these symptoms. "
06/05/2015 - "A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice."
01/01/2015 - "This study aimed to investigate the association of peroxisome proliferator-activated receptor (PPAR) genes PPARα L162V, PPARγ2 C161T and PPARδ T294C single nucleotide polymorphisms (SNPs) with obesity and metabolic syndrome (Met-S) in a multi-ethnic population in Kampar, Malaysia. "
04/01/2014 - "Although the Pro12Ala at exon B has been concerned an essential variant in the development of obesity, the lack of association of the variant with metabolic traits in this study should not be treated as impossibility or a proof of error because other factors, e.g., genes regulated by PPAR-γ, may have complicated the development of metabolic abnormalities. "
01/01/2013 - "Our study shows that RF is capable of inhibiting the differentiation of 3T3-L1 adipocytes through the modulation of PPAR γ , C/EBP α , and AMPK, suggesting that it has a potential for therapeutic application in the treatment or prevention of obesity. "
10/01/2010 - "This study failed to find significant differences in the anthropometric indicators of obesity (Body Mass Index, Waist-Hip Ratio and Total Body Fat) between the genotypes of all the PPAR and UCP gene variants. "
03/01/2004 - "In the present study, the molecular and physiological effects of seven different PPAR-activating drugs have been examined in a rodent model of dyslipidemia. "
07/01/2015 - "Nuclear peroxisome proliferator activated receptor-α (PPAR-α) plays a fundamental role in the regulation of lipid homeostasis and is the target of medications used to treat dyslipidemia. "
03/01/2015 - "Saroglitazar, a dual PPAR-α/γ agonist, is a potential therapeutic option for the management of diabetic dyslipidemia. "
01/01/2015 - "Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia. "
01/01/2015 - "While statins are irrefutably the first line of drugs for dyslipidemia management in patients with residual CV risk while on a statin, PPAR α/γ agonists have been found to be of substantial benefit. "
|5.||Fibric Acids (Fibrates)
|6.||Peroxisome Proliferator-Activated Receptors (PPAR)
|1.||Drug Therapy (Chemotherapy)